Compare TRTX & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRTX | SLDB |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.4M | 674.4M |
| IPO Year | N/A | 2017 |
| Metric | TRTX | SLDB |
|---|---|---|
| Price | $8.40 | $10.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $9.83 | ★ $16.36 |
| AVG Volume (30 Days) | 698.7K | ★ 2.5M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.55% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.57 | $3.79 |
| 52 Week High | $9.85 | $10.88 |
| Indicator | TRTX | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 46.79 | 77.01 |
| Support Level | $8.35 | $6.38 |
| Resistance Level | $8.72 | N/A |
| Average True Range (ATR) | 0.15 | 0.65 |
| MACD | -0.02 | 0.30 |
| Stochastic Oscillator | 30.61 | 99.11 |
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating-rate first mortgage loans that are secured by high-quality commercial real estate properties undergoing some form of transition and value creation.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.